For citations:
Besova NS, Titova TA, Artamonova EV, Stroyakovskiy DL, Perminova EV, Yukal’chuk DY, Ponomarenko DM, Belyak NP, Orlova RV, Teletaeva GM, Ratner EY, Mochalova AS, Gordeeva OO, Zhabina AS, Gamayunov SV, Smolin AV, Povyshev AY, Andrievskikh MI, Tryakin AA, Stilidi IS. Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia. Meditsinskiy sovet = Medical Council. 2019;(19):104-113. (In Russ.) https://doi.org/10.21518/2079-701X-2019-19-104-113
Email this article 